中国医药企业的创新转型

Innovation and Transformation of Chinese Pharmaceutical Enterprises

随着我国医改的深入和科技的进步,特别是药品集中招标采购的推进,仿制药利润越来越低,医药企业创新转型势在必行。本文分析了目前我国医药行业已具备创新转型的条件,即医保目录调整周期缩短、风险投资基金日趋活跃、海外生物医药人才的大量回归等促进了创新转型。归纳了目前我国存在的自主创新、引进创新、联合开发,投资并购等创新转型模式。通过创新转型,我国医药生物领域已由原来的单纯仿制阶段逐步进入原始创新阶段,每年均有创新产品批准上市,并有创新产品走出国门、走向世界。只有创新转型,医药企业才能形成自己的核心竞争力,我国医药行业才能健康稳定地发展。

With the deepening of healthcare reform and advancement of science and technology in China,especially with development of the centralized drug procurement mechanism,the profits of generic drugs are becoming lower and lower,and innovation and transformation are imperative for pharmaceutical enterprises.This paper analyzes the conditions for innovation and transformation within China’s pharmaceutical industry,that is,the shortening of the adjustment cycle for the national drug reimbursement list,venture capital investment becoming increasingly active,and a large number of biomedical talents returning to China,etc.Existing innovation and transformation models in China are summarized,including homegrown innovation,introduced innovation,joint development,investment and mergers&acquisitions.Through innovation and transformation,the Chinese biopharmaceutical industry has gradually transitioned from pure imitation to original innovation.Every year there are innovative products approved for marketing,and innovative products are stepping onto the global stage.Only through innovation can pharmaceutical enterprises build their core competitiveness,and the Chinese pharmaceutical industry maintain its healthy and stable development.